Lindsay Tetreault1, Branko Kopjar2, Aria Nouri1, Paul Arnold3, Giuseppe Barbagallo4, Ronald Bartels5, Zhou Qiang6, Anoushka Singh1, Mehmet Zileli7, Alexander Vaccaro8, Michael G Fehlings9. 1. Division of Neurosurgery and Spinal Program, Department of Surgery, Toronto Western Hospital, University of Toronto, 399 Bathurst St. Suite 4WW-449, Toronto, ON, M5T 2S8, Canada. 2. Department of Health Services, University of Washington, Seattle, WA, USA. 3. Department of Neurosurgery, University of Kansas, Kansas City, KS, USA. 4. Department of Neurosurgery, University Hospital Catania, Catania, Italy. 5. Department of Neurosurgery, Nijmegen Medical Centre, Radboud University, Nijmegen, The Netherlands. 6. Department of Orthopaedics, Southwest Hospital, Third Military Medical University, Chongqing, People's Republic of China. 7. Department of Neurosurgery, Ege University Faculty of Medicine, Izmir, Turkey. 8. Department of Orthopaedic Surgery, Sidney Kimmel Medical Center at Thomas Jefferson University, Philadelphia, PA, USA. 9. Division of Neurosurgery and Spinal Program, Department of Surgery, Toronto Western Hospital, University of Toronto, 399 Bathurst St. Suite 4WW-449, Toronto, ON, M5T 2S8, Canada. michael.fehlings@uhn.ca.
Abstract
PURPOSE: We aimed to determine cut-offs between mild, moderate and severe myelopathy on the modified Japanese Orthopedic Association (mJOA) score. METHODS: Between December 2005 and January 2011, 757 patients with clinically diagnosed DCM were enrolled in the prospective AOSpine North America (n = 278) or International (n = 479) study at 26 sites. Functional status and quality of life were evaluated at baseline using a variety of outcome measures. Using the Nurick score as an anchor, receiver operating curve (ROC) analysis was conducted to determine cut-offs between mild, moderate and severe disease. The validity of the identified cut-offs was evaluated by examining whether patients in different severity groups differed in terms of impairment, disability, quality of life and number of signs and symptoms. RESULTS: A mJOA of 14 was determined to be the cut-off between mild and moderate myelopathy and a mJOA of 11 was the cut-off score between moderate and severe disease. Patients in the severe myelopathy group (n = 254) had significantly reduced quality of life and functional status and a greater number of signs and symptoms compared to patients classified as mild (n = 190) or moderate (n = 296). CONCLUSIONS: Mild myelopathy can be defined as mJOA from 15 to 17, moderate as mJOA from 12 to 14 and severe as mJOA from 0 to 11. These categories should be adopted worldwide to standardize clinical assessment of DCM.
PURPOSE: We aimed to determine cut-offs between mild, moderate and severe myelopathy on the modified Japanese Orthopedic Association (mJOA) score. METHODS: Between December 2005 and January 2011, 757 patients with clinically diagnosed DCM were enrolled in the prospective AOSpine North America (n = 278) or International (n = 479) study at 26 sites. Functional status and quality of life were evaluated at baseline using a variety of outcome measures. Using the Nurick score as an anchor, receiver operating curve (ROC) analysis was conducted to determine cut-offs between mild, moderate and severe disease. The validity of the identified cut-offs was evaluated by examining whether patients in different severity groups differed in terms of impairment, disability, quality of life and number of signs and symptoms. RESULTS: A mJOA of 14 was determined to be the cut-off between mild and moderate myelopathy and a mJOA of 11 was the cut-off score between moderate and severe disease. Patients in the severe myelopathy group (n = 254) had significantly reduced quality of life and functional status and a greater number of signs and symptoms compared to patients classified as mild (n = 190) or moderate (n = 296). CONCLUSIONS: Mild myelopathy can be defined as mJOA from 15 to 17, moderate as mJOA from 12 to 14 and severe as mJOA from 0 to 11. These categories should be adopted worldwide to standardize clinical assessment of DCM.
Entities:
Keywords:
Defining disease severity; Degenerative cervical myelopathy; Functional impairment; Measurement; Modified Japanese Orthopaedic Association scale
Authors: Lindsay Tetreault; Christina L Goldstein; Paul Arnold; James Harrop; Alan Hilibrand; Aria Nouri; Michael G Fehlings Journal: Neurosurgery Date: 2015-10 Impact factor: 4.654
Authors: Sukhvinder Kalsi-Ryan; Anoushka Singh; Eric M Massicotte; Paul M Arnold; Darrel S Brodke; Daniel C Norvell; Jeffrey T Hermsmeyer; Michael G Fehlings Journal: Spine (Phila Pa 1976) Date: 2013-10-15 Impact factor: 3.468
Authors: Lindsay Tetreault; Aria Nouri; Branko Kopjar; Pierre Côté; Michael G Fehlings Journal: Spine (Phila Pa 1976) Date: 2015-11 Impact factor: 3.468
Authors: Wen Jie Choy; Lingxiao Chen; Camila Quel De Oliveira; Arianne P Verhagen; Omprakash Damodaran; David B Anderson Journal: J Spine Surg Date: 2022-03
Authors: Zamir Merali; Justin Z Wang; Jetan H Badhiwala; Christopher D Witiw; Jefferson R Wilson; Michael G Fehlings Journal: Sci Rep Date: 2021-05-18 Impact factor: 4.379